尽管嵌合抗原受体（CAR）T细胞疗法在治疗B细胞淋巴瘤和白血病方面显示出了显著的疗效，但对T细胞恶性肿瘤的研究仍然有限。在这里，我们报告了一例对多种化疗方案无效的肝脾γδ T细胞淋巴瘤患者，通过人白细胞抗原（HLA）完全不匹配的同胞衍生CD7 CAR-T细胞疗法最终取得了首次完全缓解，并经流式细胞术确认无最低残留疾病。然而，由于异基因性质，CAR-T细胞在达到循环T细胞的顶峰值83.4%后迅速下降。细胞因子释放综合征、细胞减少和感染等副作用在治疗后是可控的。在巩固性半相合性造血干细胞移植（HSCT）后，在随访结束时（CAR-T输注后13个月）患者仍保持缓解。这是首例通过HLA完全不匹配的同胞衍生CD7 CAR-T细胞疗法桥接到半相合性HSCT后实现持久缓解的复发/难治性肝脾γδ T细胞淋巴瘤病例。

While chimeric antigen receptor (CAR)-T-cell therapy has demonstrated remarkable effectiveness in the treatment of B-cell lymphomas and leukemias, research on T-cell malignancies is still limited. Here, we reported a patient with hepatosplenic γδ T-cell lymphoma refractory to multiple lines of chemotherapy, who eventually achieved first complete remission with flow cytometry-confirmed minimal residual disease negativity after human leukocyte antigen (HLA) fully-mismatched sibling-derived CD7 CAR-T therapy. However, given the allogeneic nature, CAR-T cells dropped rapidly after a peak of 83.4% of circulating T-cells. Cytokine release syndrome, cytopenia, and infections occurred but were manageable after treatments. After the consolidative haploidentical hematopoietic stem cell transplantation (HSCT), the patient remained in remission at the end of the follow-up (13 months post-CAR-T infusion). This is the first case of relapsed/refractory hepatosplenic γδ T-cell lymphoma who achieved lasting CR after HLA fully-mismatched sibling-derived CD7 CAR-T therapy bridging to haploidentical HSCT.